Hemoglobin A1C (glycated hemoglobin) is a test for determining the average blood glucose levels over an extended period of time, and is often used to evaluate glucose control in diabetics. The hemoglobin A1C levels are abnormally low because the life span of the red blood cells is decreased - providing less time for the non-enzymatic glycosylation of hemoglobin. Thus, even with high overall blood sugar, the A1C will be lower than expected. Iron overload. Leg ulcer. Deep vein thrombosis (DVT). Cardiovascular disease. Research
Modern ongoing research interests:

Experimental gene therapy exists to treat hereditary spherocytosis in lab mice; however, this treatment has not yet been tried on humans due to all of the risks involved in human gene therapy. Bone marrow transplant. Paradoxical endurance-based athleticism associated with hereditary spherocytosis. Evolution of spherocytic erythrocyte adaptation in those of Northern European and Japanese descent. Increased ability to defend against viral infections in hereditary spherocytosis patients. See also
Spherocytosis
Anemia
Hematology

References
External links

A short article from WebMD
A picture of spherocytes from Medline
Magnesium salicylate is a common analgesic and nonsteroidal anti-inflammatory drug (NSAID) used to treat mild to moderate musculoskeletal pain such as in tendons and muscles. It is also used to treat joint pain like arthritis, general back pain, and headaches.It is found in a variety of over-the-counter (OTC) medications, most notably the brand Doans Pills, as an anti-inflammatory, primarily for back-pain relief. Magnesium salicylate can be an effective OTC alternative to prescription NSAIDs, with both anti-inflammatory and pain-relieving effects. Controversy
While magnesium salicylate is sold as an alternative for pain relief, it is still a nonsteroidal anti-inflammatory drug and, like others in this class, can cause stomach ulcers,  without any proven superiority to other over-the-counter pain relievers. Novartis, the company (formerly known as Ciba or Ciba-Geigy Corp.) that produces Doans Pills, has claimed that the product is superior in providing back pain relief. In June 1996, the US Federal Trade Commission (FTC) charged the company with violating federal law with its unsubstantiated claim. In March 1998, the court ruled in favor of the FTC, but there was no stipulation about how the company should or would have to amend its advertising/packaging. Thus, Doans was able to continue marketing as a "superior treatment for back pain".